Yale Cancer Center | Strategic Alliance Partners

Yale Cancer Center (YCC) is one of only 51 National Cancer Institute-designated comprehensive cancer centers in the nation and the only such center in Connecticut. Cancer treatment for patients is available at Smilow Cancer Hospital through 13 multidisciplinary teams and at 15 Smilow Cancer Hospital Care Centers in Connecticut and Rhode Island. Comprehensive cancer centers play a vital role in the advancement of the NCI’s goal of reducing morbidity and mortality from cancer through scientific research, cancer prevention, and innovative cancer treatment.

Latest from Yale Cancer Center

Pursuing New Paradigms in Prostate Cancer

January 14, 2021

Podcast

In today’s episode, we had the pleasure of speaking with the faculty of a recent Institutional Perspectives in Cancer webinar on prostate cancer hosted by Yale Cancer Center.

Dr. Sznol on the Multidisciplinary Management of Immunotherapy-Associated Toxicities in Melanoma

January 11, 2021

Video

Mario Sznol, MD, Yale Cancer Center, discusses the multidisciplinary management of toxicities associated with immunotherapy in patients with melanoma.

Dr. Sznol on Toxicities Associated With Immunotherapy in Melanoma

January 07, 2021

Video

Mario Sznol, MD, discusses toxicities associated with immunotherapy in patients with melanoma.

Dr. Herbst on the Approval of Adjuvant Osimertinib in EGFR+ NSCLC

January 06, 2021

Video

Roy S. Herbst, MD, PhD, discusses the approval of adjuvant osimertinib in EGFR-positive non–small cell lung cancer.

Petrylak Shares Selection Considerations for Available Agents in Hormone-Sensitive Prostate Cancer

December 29, 2020

Article

Daniel P. Petrylak, MD, highlights the use of abiraterone acetate, enzalutamide, and apalutamide and how these agents can lead to improvements in overall survival and progression-free survival in patients with hormone-sensitive prostate cancer.

Antiandrogens Plus ADT Continue to Reign Supreme in Nonmetastatic CRPC

December 28, 2020

Article

Michael E. Hurwitz, MD, PhD, highlights the role of second-generation androgen blockers in nonmetastatic castration-resistant prostate cancer, how these agents compare, and active areas of investigation.